Efficacy of cyclin-dependent kinases 4 and 6 inhibitors in the treatment of HR +/HER2 − advanced breast cancer: a meta-analysis
Abstract Aim This study investigates the efficacy and safety of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) in treating hormone receptor-positive (HR +), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Methods A systematic r...
Saved in:
| Main Authors: | Isah Adamu Danbala, Xu Wang, Yuting Su, Haowen Tang, Wanying Sheng, Zakari Shaibu, Iliyasu Isah, Xiao Yuan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40001-025-02806-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors
by: E. V. Artamonova, et al.
Published: (2019-09-01) -
Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors in silico
by: Kaori Asamitsu, et al.
Published: (2025-06-01) -
Grade III rash induced by abemaciclib in a patient with HR+/HER-2 negative breast cancer
by: Yu Yao, et al.
Published: (2025-05-01) -
Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer
by: Razia Rahman, et al.
Published: (2025-05-01) -
Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review
by: N. A. Avxentyev, et al.
Published: (2024-05-01)